Barclays raised the firm’s price target on Edwards Lifesciences to $101 from $100 and keeps an Overweight rating on the shares. The firm is updating its price target to reflect the company’s Q1 upside while forecasting sequential improvements in operating performance, supported by an increasing contribution from TMTT, or Transcatheter Mitral and Tricuspid Therapies, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $85 from $86 at Canaccord
- Edwards Lifesciences price target raised to $95 from $92 at UBS
- Edwards Lifesciences backs FY24 EPS view $2.70-$2.80, consensus $2.75
- Edwards Lifesciences sees Q2 adjusted EPS 67c-71c, consensus 70c
- Edwards Lifesciences reports Q1 adjusted EPS 66c, consensus 64c